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Penjujukan Kromosome 4 Manusia dan Analisis Polimorfisme Nukleotida 
Tunggal (SNP) daripada Individu Achondroplasia  
 
Abstrak 
Achondroplasia adalah penyebab paling umum kekerdilan manusia yang 
beranggota pendek dan mempengaruhi seramai 250,000 orang di seluruh dunia. 
Penyakit genetik ini menyebabkan pelbagai komplikasi dari segi sosial dan perubatan. 
Kebanyakan kes achondroplasia berlaku secara rawak dan disebabkan oleh mutasi de 
novo. Gangguan autosomal-dominan ini disebabkan oleh mutasi tunggal dalam gen 
reseptor jenis 3 faktor pertumbuhan fibroblas (FGFR3). Kajian ini menumpukan 
pemahaman tentang genetik achondroplasia dengan mengenalpasti SNP daripada 
kromosom seorang sukarelawan achondroplasia berasal dari Asia. Kaedah 
pewarnaan kromosom dan penkariotipan aliran bivariat kromosom manusia telah 
berjaya dioptimumkan. Amplifikasi genom keseluruhan (WGA) telah dilakukan 
untuk menjana data penjujukan truput tinggi. Analisis data penjujukan dan SNP yang 
menyeluruh tidak dapat mengenalpasti mutasi yang telah diketahui untuk 
achondroplasia dan hypochondroplasia. Justeru, kajian ini menunjukkan bahawa 
penanda gen achondroplasia yang klasik, iaitu gen fgfr3 bukan satu-satunya penanda 
dalam kes tertentu ini.  
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Human Chromosome 4 Sequencing and Single Nucleotide Polymorphism (SNP) 
Analysis of an Achondroplasia Individual  
 
Abstract 
Achondroplasia is the most common cause of short-limbed dwarfism in 
humans, affecting 250,000 individuals worldwide. This genetic disorder results in 
various social and medical complications. The majority of achondroplasia cases is 
sporadic and result from de novo mutations. This autosomal-dominant disorder is 
caused by single nucleotide mutations in the gene encoding the type 3 receptor for 
fibroblast growth factor (FGFR3). This study focused on understanding the genetic 
basis of achondroplasia by identifying SNPs from flow-sorted human chromosomes 
of an achondroplasia volunteer of Asian origin. Chromosome staining and the 
bivariate flow karyotyping of human chromosomes were successfully optimized. 
Whole Genome Amplification (WGA) was carried out to generate high-throughput 
sequencing data. Thorough analysis of the sequence data and SNPs was unable to 
identify any known mutations of achondroplasia and hypochondroplasia. Thus, it 
indicates that the classical achondroplasia indicator gene, fgfr3, may not be the only 
indicator in this particular case.  
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Why am I different? 
Living as a shorter person in a world that‟s designed for the tall people – Why 
am I different? – is the most frequently asked question I always have.  
I look different. Everywhere I go, I attract curiosity and I get stared at a lot. As 
far as I know, I have what I think is an ordinary life. I live with my parents and two 
sisters. I do not notice the little things that I have to do differently from other people. 
I felt that I am a normal person, living a normal life. I eat, sleep, breathe, study and 
get ill, just like everyone else. But why am I still different? 
I know that some little people like me have a lot of health problems. Personally, 
I have walking problems and get more back and joint pain than others my age but 
this certainly is not enough to stop me to go for sports or activities that I enjoy. Thus, 
I want to change the lifestyle of a little person, who have more serious health 
problems than I do, to enable them to lead a normal life like other people.  
As Nobel laureate Paul Berg of Stanford University mentioned before “All 
human disease is genetic in origin.” So, how do I investigate the mystery of the genes 
that made me different and find the answer to my question?  
Since the completion of the Human Genome Project, the sequence of the 
human genome is providing the complete view of the genetic heritage. The human 
genome, the complete set of human genes, comes in 23 separate pairs of 
chromosomes. If a human genome is a book, then every human being has a story to 
tell. Each book comes in 23 chapters, which are called chromosomes. Each chapter 
contains stories, called genes. Here, I will be telling you the story of one of the 
chapters in my book, chromosome 4, and focusing one of the stories, the fgfr3 gene 
that is related to a one of the best-known genetic diseases, Achondroplasia.  
xiv 
 
Single-nucleotide polymorphisms (SNPs) are one-base variations in DNA 
sequence. Each person‟s genetic material contains a unique SNP pattern that is made 
up of many different genetic variations. Most SNPs are not responsible for a disease 
state. Instead, they can often be helpful when trying to find genes responsible for 
inherited diseases and serve as biological markers for pinpointing a disease on the 
human genome map. Occasionally, a SNP may actually cause a disease. Therefore, it 
can be used to search for and isolate the disease-causing gene. 
Achondroplasia has been mapped to the tip of the short arm of chromosome 4. 
So, how can we better understand this genetic disorder? There are two possible ways: 
1. Sequence a full human genome and analyze the presence of SNPs, or 
2. Study chromosome 4 in-depth and compare the SNP patterns between 
individuals affected by achondroplasia and individuals unaffected by the 
genetic disorder. 
At the moment, since achondroplasia-associated mutations are already known 
to be located in chromosome 4, I will first study specifically chromosome 4 to 
identify SNPs that could be related to the achondroplasia disease family. Now, how 
can I identify and isolate chromosome 4 from the 23 pairs of chromosomes? One 
possible way is to use a rapidly developing technique in research and clinical practice, 
the flow cytometry and sorting instrument. The flow cytometry technique enables us 
to isolate the desired chromosome from the other chromosomes. Directly after 
isolation, the flow-sorted chromosomes can be sequenced to determine the nucleotide 
sequence. As human DNA sequences are 99.9% identical to each other, the 0.1% of 
variation can provide many clues to many diseases and common illnesses. The 
identification of such variations can help explore the mystery of achondroplasia. 
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CHAPTER 1  
INTRODUCTION 
1.1 Achondroplasia 
1.1.1 Overview 
Achondroplasia is a Greek word which means “without cartilage formation”. 
This disorder has been present for ages. In fact, people suffering from achondroplasia 
were used as subjects for art. One of the most famous posterity with the characteristic 
phenotype of achondroplasia recorded by the artistic community is the portrait of 
Don Sebastián de Morra (Figure 1.1A), a courtier of Philip V of Spain (Young, 1998), 
by Velázquez. Achondroplasia was also mentioned in ancient Egypt. Seneb, a 
Dynasty dwarf, was the chief of the royal wardrobe and priest of the funerary cults of 
Khufu. A statue still exists of him and it depicts him with his family, including his 
wife who was of normal stature (Figure 1.1B). Even ancient Egyptian gods such as 
Bes have been depicted as suffering from achondroplasia (Figure 1.1C) (Kozma, 
2006). In fact, throughout history, in the ancient times, many superstitions have been 
associated with achondroplasia. When a child was born with this condition, it was 
assumed that it had occurred due to the activities of demons, as a punishment meted 
out by the gods, or as a result of the movements of the stars and moon.  
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Figure 1.1 History of achondroplasia. (A) The portrait of The Dwarf Don Sebastián 
de Morra, by Velázquez. (B) Seneb status with his wife and their 
children. (C) Bes statue from Egypt. 
 
Achondroplasia is the most common form of non-lethal skeletal dysplasia. It is 
the one of the best-known and most frequent cause of short-limbed dwarfism in 
human beings. Achondroplasia has an incidence rate between one in every 10,000 to 
one in every 30,000 live births (Oberklaid et al., 1979). More than 85% of 
achondroplasia cases are sporadic; they are associated with de novo mutation (Vajo 
et al., 2000) and have no familial history. Achondroplasia is estimated to affect more 
than 250,000 individuals worldwide (Baujat et al., 2008).  
The achondroplasia family is characterized by a continuum of severity ranging 
from mildly affected hypochondroplasia and severe achondroplasia with 
developmental delay and acanthosis nigricans (SADDAN) to lethal neonatal 
dwarfism, thanatophoric dysplasia (TD). In individuals with achondroplasia, the 
skeleton is the primary system involved in the phenotype. All of the disorders in the 
achondroplasia family of skeletal dysplasias involve some degree of short stature 
and/or abnormal ossification of bone structures (Vajo et al., 2000). 
Hypochondroplasia typically present with a mild short stature and a stocky build. TD 
is much more severe in general and is usually lethal in the prenatal period. SADDAN 
A B C 
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refers to a clinical phenotype intermediate in severity between TD and 
achondroplasia. 
Achondroplasia is a disease with shortness in appearance. The characteristics 
of dwarfism of achondroplasia are so distinctive that they are not difficult to be 
identified (Castiglia, 1996). Many affected foetuses are recognized in the third 
trimester of pregnancy. Individuals with achondroplasia are characterized by a long 
and narrow trunk, short limbs, a large head with a prominent forehead (Figure 1.2A) 
and a flat depressed nasal bridge (Richette et al., 2008), curved spine (Figure 1.2B), 
and short hands and fingers with a trident appearance (Figure 1.2C). The average 
adult height for achondroplasia for both male and female is approximately 4 feet 
(Baujat et al., 2008; Castiglia, 1996). 
                
  
 
Figure 1.2 Features of achondroplasia individual. (A) Body disproportion with short 
limbs, relatively long trunk, and large head (Genetic People, 2009). (B) 
Bending of the spine occurring in the middle and lower back (Nemours 
Foundation, 2009). (C) Trident hands with short fingers (Nemours 
Foundation, 2009). 
 
Even though the most striking feature of achondroplasia involves cartilage 
growth, the achondroplasia mutation affects many organ systems (Horton et al., 
2007). Many health problems appear at predicted ages, including adulthood. They 
can be minimized if detected early. Thus, guidelines for individuals with 
A B C 
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achondroplasia have been developed in several countries (Horton et al., 2007; Hunter 
et al., 1998; Trotter and Hall, 2005) to aid physicians in preventive care.  
In achondroplasia, various medical complications are consequences of the 
abnormal linear bone growth. Children with achondroplasia generally have delayed 
motor milestones such as delays in sitting and walking. It has been reported that 
tibial bowing, leg and lower back pain are considered to be the hallmarks of 
achondroplasia (Hunter et al., 1998). Respiratory complications also make a major 
contribution to achondroplasia, especially in young children (Young, 1998). Sleep 
dysfunction, including snoring and apnoea, are common in achondroplasia both 
during daytime and sleep. Apnoea may increase the risk of sudden unexpected death 
in infants (Hecht et al., 1987). Otitis media or middle ear disease occurs frequently, 
which will lead to hearing loss if untreated. Speech delay and articulation problems 
are also recognized complications in achondroplasia. Furthermore, obesity is a major 
problem in achondroplasia. It can contribute to the potential early cardiovascular 
mortality in this condition. Occasionally, orthodontic problems such as dental 
crowding is observed in achondroplasia because of the jaw shortness (Hunter et al., 
1998). In addition to all the medical complications, psychological difficulties such as 
depression are also common among individuals with achondroplasia (Baujat et al., 
2008), resulting from the stressful situation required to adapt and cope to the world 
of taller people.  
Even though individuals with achondroplasia run a higher risk for certain 
health problems, they are able to live a full, normal, and independent life. Most 
individuals with achondroplasia have normal mental faculties and intelligence (Vajo 
et al., 2000). Although serious problems may arise during infancy, they affect only 5% 
to 10% of infants with achondroplasia (Trotter and Hall, 2005). 
 5 
 
In addition, individuals with achondroplasia can also lead a productive life. 
Sexual development and fertility seems to be normal in achondroplasia-affected 
women who opt for childbearing (Horton et al., 2007; Richette et al., 2008). The 
diagnosis of achondroplasia in the foetus is made with certainty when one or both 
parents have this condition. Fifty percent of the offspring of individuals with 
achondroplasia will be affected (Baujat et al., 2008). When both parents have typical 
achondroplasia, their children with homozygous achondroplasia generally do not 
survive beyond a few weeks or possibly a few months (Castiglia, 1996). 
 
1.1.2 Human chromosome 4  
Chromosome 4 is one of the 23 pairs of chromosomes in humans. 
Chromosome 4 contains approximately 190 million base pairs and comprises 6.5 
percent of the total human genomic DNA (Gusella et al., 1986). Hillier et al. (2005) 
have identified 796 protein-coding genes and 778 pseudogenes on chromosome 4. 
Chromosome 4 contains the highest percentage of the long interspersed nucleotide 
element (LINE) content across all autosomes. However, the short interspersed 
nucleotide element (SINE) content is lower than the autosomal average. One of the 
highest (G+C) content windows in the genome is also found on chromosome 4. 
Hillier et al. (2005) also identified 1,004 CpG islands in chromosome 4 (5.4 per Mb), 
analyzed based on 186 million base pairs, each with an average length of 
approximately 800 bp. Chromosome 4 has the lowest density of predicted CpG 
islands and the lowest average recombination rate of any of the chromosomes 
(Hillier et al., 2005).  
Identifying genes on each chromosome is an active area of genetic research. As 
researchers use different approaches to predict the number of genes on each 
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chromosome, the estimated number of genes varies. Some of the famous diseases 
related to genes located on chromosome 4 are Huntington disease, Ellis-van Creveld 
syndrome, and Parkinson disease.  
The gene responsible for achondroplasia was genetically mapped to the short 
arm of chromosome 4, 4p16.3 (Le Merrer et al., 1994; Velinov et al., 1994). 
Significantly, it was mapped very close to another elusive disease gene locus, the 
Huntington disease. Together with the discovery of the gene causing Huntington‟s 
disease, increased interest was generated towards this chromosome (Figure 1.3). 
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Figure 1.3 Human chromosome 4 and diseases mapped to the chromosome. Adapted 
from U.S. Department of Energy Genome Program (DNARSS.com, 
2009). 
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1.1.3 Fibroblast growth factor receptor 3 (FGFR3) 
The gene causing achondroplasia was discovered by Dr. John Wasmuth 
(Shiang et al., 1994). While working with his colleagues, Wasmuth discovered that a 
mutation in the fibroblast growth factor receptor 3 (fgfr3) gene caused this 
autosomal-dominant disorder. In 1993, Keegan et al. reported that the fgfr3 gene 
localizes to human chromosome 4p16.3, confirming the existence of fgfr3 genes 
(Keegan et al., 1993). The identified causative mutations in fgfr3 responsible for 
achondroplasia showed that a mutation in a transmembrane domain of this fibroblast 
growth factor receptor results in a skeletal growth defect (Rousseau et al., 1994).  
FGFR3 plays an important role in long bone development. FGFR3 belongs to 
the fibroblast growth factor receptor family. FGFR3 is one of the four FGFR 
members (FGFR 1-4), which share a common organization comprising three 
extracellular immunoglobin-like loops (Ig I-III), a single hydrophobic 
transmembrane region (TM), and two cytoplasmic tyrosine kinase (TK) subdomains 
TK1 and TK2 (Figure 1.4) (Schlessinger, 2000). The fgfr3 gene contains an open 
reading frame of 2905 nucleotides and consists of 19 exons and 18 introns (Table 
1.1).  
             
 
Figure 1.4 Structure and organization of the human fgfr3 gene. Numbers above the 
arrows and the vertical dashed lines indicate the positions of intron and 
exon sequences, respectively. Sizes of both introns and exons are not 
drawn to scale (Wuchner et al., 1997).  
 
Intron 
Exon 
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Table 1.1 Exon and intron sizes of the human fgfr3 gene (Wuchner et al., 1997) 
 
Exon Exon size (bp) Intron Intron size (bp) 
1 171 1 368 
2 211 2 5210 
3 270 3 223 
4 66 4 1554 
5 170 5 83 
6 124 6 91 
7 191 7 888 
8 151 8 627 
9 145 9 492 
10 191 10 303 
11 146 11 385 
12 122 12 82 
13 111 13 80 
14 191 14 110 
15 123 15 83 
16 71 16 218 
17 138 17 145 
18 106 18 181 
19 207 - - 
 
FGFR3 is one of many important local physiological regulators of linear bone 
growth (Horton and Lunstrum, 2002). Studies suggested that FGFR3 was a negative 
regulating factor of endochondral ossification (Deng et al., 1996). It binds with the 
fibroblast growth factors (FGFs). From the 22 known FGF ligands, the exact 
physiological ligands for FGFR3 is not known, although FGFs 2, 4, 9, and 18 are 
probably the best candidates based on the distribution of expression and ability to 
bind and activate FGFR3 (Horton et al., 2007). The developmental expression 
pattern of FGFR3 suggests that this protein plays a significant role in skeletal/bone 
development (Vajo et al., 2000). Direct evidence for the discovery that mutations in 
the coding sequences of fgfr3 gene cause bone abnormalities in humans was reported 
by Rousseau et al. (1994). 
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1.1.4 Genetics of achondroplasia 
The clinical spectrum of the achondroplasia family of disorders is caused by 
different mutations in fgfr3. In most cases of achondroplasia, the genetic abnormality 
is due to a mutation located within a critical region of fgfr3 (Richette et al., 2008). It 
has been demonstrated that all new mutations occur on the mutated allele from a 
paternal origin, suggesting increased mutability of fgfr3 by an increased paternal age 
at the time of conception (Wilkin et al., 1998). Almost all individuals with 
achondroplasia are caused by one of two point mutations in the gene for fgfr3 
(Young, 1998). The mutations are a G-to-A transition (G1138A) and a G-to-C 
transition (G1138C) in nucleotide 1138 of the fgfr3 gene (Bellus et al., 1995). Both 
mutations result in the same amino acid substitution (Gly380Arg) in the 
transmembrane domain of FGFR3 (Figure 1.5) (Baujat et al., 2008). The relatively 
high incidence of achondroplasia suggests that nucleotide 1138 of the fgfr3 gene is 
the most mutable nucleotide described so far in the human genome (Vajo et al., 
2000).  
Hypochondroplasia is caused by mutations in tyrosine kinase domain 1 
(Asn540Lys, Asn540Thr, or Asn540Ser) and tyrosine kinase domain 2 (Lys650Asn 
and Lys650Gln). Additional substitutions occur at positions 538 (Ile538Val), 278 
(Tyr278Cys), and 84 (Ser84Leu) (Grigelioniene et al., 2000). Several mutations in 
the extracellular domain or the stop codon (Vajo et al., 2000) are associated with 
thanotophoric dysplasia type I, while a mutation in tyrosine kinase domain 2 
(Lys650Glu) is associated with thanatophoric dysplasia type II, which is also lethal 
but less severe (Figure 1.5 and Table 1.2).  
The findings in individuals with achondroplasia prompted the search for fgfr3 
mutations in other disorders considered related to achondroplasia (Vajo et al., 2000). 
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For instance, a G-to-A transition in nucleotide 1172 has been identified in individuals 
with Crouzon syndrome with Acanthosis Nigricans, resulting in an Ala391Glu 
(A391E) substitution in the transmembrane domain. On the other hand, Muenke 
syndrome has a Pro250Arg (P250R) amino acid substitution, caused by a C-to-G 
transition at position 749 of the coding cDNA sequence. 
 
 
 
 
Figure 1.5 FGFR3 mutations identified in chondrodysplasias (Baujat et al., 2008). 
Adapted from Figure 5, page 12, Baujat et al., 2008. 
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Table 1.2 Nucleotide transitions and amino acid substitutions in achondroplasia 
family 
 
Achondroplasia 
family  
Mutation Substitution 
resulted 
References 
Achondroplasia G1138A/G1138C 
T1130G 
G1123T 
G1037A 
Gly380Arg  
Leu377Arg  
Gly375Cys  
Gly346Glu 
(Rousseau et al., 1994) 
(Heuertz et al., 2006) 
(Chen et al., 1999) 
(Baujat et al., 2008) 
Hypochondroplasia C1659A/C1659G 
A1658C 
 
A1658G 
A1651G 
 
G1950T/G1950C 
A1948C 
A831T 
A829G 
C251T 
G801T 
A783C 
C597T 
A983T 
G879T 
C1052G 
G1081A 
Asn540Lys  
Asn540Thr  
 
Asn540Ser 
Ile538Val  
 
Lys650Asn  
Lys650Gln  
Ser279Cys 
Tyr278Cys  
Ser84Leu 
Gly268Cys  
Asn262His  
Arg200Cys  
Asn328Ile  
Gly295Cys 
Ser351Cys 
Glu360Lys 
(Bellus et al., 2000) 
(Grigelioniene et al., 
2000) 
(Baujat et al., 2008) 
(Grigelioniene et al., 
2000) 
(Bellus et al., 2000) 
(Bellus et al., 2000) 
(Heuertz et al., 2006) 
(Heuertz et al., 2006) 
(Heuertz et al., 2006) 
(Heuertz et al., 2006) 
(Heuertz et al., 2006) 
(Heuertz et al., 2006)  
(Bellus et al., 2000) 
(Baujat et al., 2008) 
(Baujat et al., 2008) 
(Baujat et al., 2008) 
Thanatophoric 
dyplasia (TD)  
Type I  
C742T 
C746G 
A1111T 
T2458G 
T2458A 
A2460T 
G1108T 
A1118G 
Arg248Cys  
Ser249Cys  
Ser371Cys  
Stop807Gly  
Stop807Arg  
Stop807Cys  
Gly370Cys  
Tyr373Cys  
(Rousseau et al., 1996) 
(Rousseau et al., 1996) 
(Rousseau et al., 1996) 
(Rousseau et al., 1996) 
(Rousseau et al., 1996) 
(Rousseau et al., 1996) 
(Rousseau et al., 1996) 
(Rousseau et al., 1996) 
Thanatophoric 
dyplasia (TD)  
Type II 
A1948G Lys650Glu  (Tavormina et al., 1999) 
Severe 
achondroplasia with 
developmental delay 
and Acanthosis 
nigricans 
(SADDAN) 
A1949T Lys650Met   (Tavormina et al., 1999) 
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1.1.5 Single nucleotide polymorphisms (SNPs)  
SNP (pronounced „S‟ „N‟ „P‟ or „SNiP‟) stands for Single Nucleotide 
Polymorphism. SNPs are the most common and abundant form of genetic variation 
in humans (Taillon-Miller et al., 1998). Simply put, they are single base pair 
positions in genomic DNA at which different sequence alternatives exist in normal 
individuals in some populations. SNPs commonly occur at a rate greater than 1% in a 
given population. About 90% of all the sequence variation recorded in the human 
genome is due to SNPs (Collins et al., 1997). In the human genome, over 3 million 
SNPs have been identified (Brookes, 1999). The typical frequency in which a single 
base differs in the genomic DNA from two equivalent chromosomes is one per 
kilobase pair of sequence (Taillon-Miller et al., 1998). It is estimated that over 99% 
of the human genome sequence is conserved across various populations. 
One of the most frequently reported mutations found in the majority of 
achondroplasia-affected individuals is the G-to-A transition (G1138A) in nucleotide 
1138 of the fgfr3 gene (Bellus et al., 1995), resulting in the amino acid substitution in 
the transmembrane domain of FGFR3 (Gly380Arg).  
Genetic factors such as SNPs may not directly cause disease but confer 
susceptibility or resistance to a disease or determine the severity or progression of 
disease (Collins et al., 1998). SNPs can help determine the likelihood that someone 
will develop a particular disease. They can have a major impact on the way humans 
respond to disease and environmental insults such as bacteria, viruses, toxins, 
chemicals, drugs, and other therapies. This makes SNPs of great value for biomedical 
research and for developing pharmaceutical products or medical diagnostics. SNPs 
are also evolutionarily stable; they do not change significantly from generation to 
generation, making them easier to follow in population studies. 
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SNPs occur in both coding regions as well as non-coding regions. Most SNPs 
fall in the non-coding region of the human genome, presumably due to lower 
selection pressure. The frequency of SNPs in the coding region is observed to be 4-
fold lower than in non-coding regions (Collins et al., 1997) because such sequence 
alterations can result in changing the transcript and hence the corresponding protein. 
Therefore, the SNPs in these regions have a direct capability to significantly impact 
the shape, structure, or a critical residue in the protein which might ultimately result 
in aberrant function of the protein and result in a disease. 
Of the SNPs that are near or in a gene, their effect on function is difficult to 
determine. SNPs are generally classed by genomic location. SNPs can fall within the 
coding regions, regulatory regions, in exons, or within introns. Non-synonymous 
SNPs (nsSNP) alter the amino acid sequence of the protein product through amino 
acid substitution. A variant may also affect the expression or translation of a gene 
product, either by interrupting a regulatory region or by interfering with normal 
splicing and mRNA function. This can include regulatory SNPs (rSNP), synonymous 
SNPs (sSNP), and intronic SNPs (iSNP). The two types of variation that are usually 
studied are polymorphisms with known phenotype and phenotypically annotated or 
disease-associated variation. Human mutations are often inferred to be disease-
associated (Mooney, 2005).  
Most SNPs do not directly result in disease since most diseases are due to 
aberrant errors in a number of genes, such as in cancer, heart diseases, and diabetes 
(Houlston and Peto, 2004; Pharoah et al., 2004). However, there are some diseases 
that have been linked to a single gene, such as Huntington‟s disease, haemophilia, or 
sickle cell anemia. Variation does not occur randomly across genetic sequences and 
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often occurs in hotspots (Benzer, 1961). It is likely that selection has played a role in 
the evolution of human genetic variation (Akey et al., 2002; Fay et al., 2001).   
 
1.1.6 Treatment 
A single nucleotide change in the human genome can make such a big 
appearance difference in a human being. The mortality rate in individuals with 
achondroplasia is higher than the general population, particularly during childhood. 
The cause of this increased mortality rate in young children is attributable to severe 
cervicomedullary compression (Hunter et al., 1998). Until today, current therapies 
for the short stature in achondroplasia are still debated as there is no treatment that 
exists to reverse the genetic abnormality of achondroplasia. Administrations of 
growth hormone and surgical limb-lengthening procedures have been proposed 
(Seino et al., 2000). Human growth hormone therapy has been used as a treatment 
for the short stature in children with achondroplasia. Although there has been some 
increase in growth rate reported, long-term benefits are not conclusive. Thus, most 
experts do not recommend such treatment for achondroplasia (Horton et al., 2007). 
Surgical limb-lengthening is another approach using several surgical and orthopaedic 
appliances. It involves breaking bones, followed by slow stretching during the 
healing process (Horton et al., 2007). However, this procedure remains arduous with 
a high risk of infection, joint and soft tissue damage, and may result in a poorer 
quality of life (Aldegheri et al., 1988).  
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1.2 Flow cytometry 
1.2.1 Overview of flow cytometry 
Flow cytometry is an extremely powerful and exciting technology involving 
the analysis of fluorescence and light scatter properties of microscopic particles at 
high speed. It allows the individual measurement of physical and chemical 
characteristics of particles as they pass one by one through a light source. The 
method was originally developed for the analysis of blood cells. Currently, most flow 
cytometers are used to evaluate human cells stained with various dyes and labelled 
with a variety of antibodies. The range of applications has continued to increase and 
encompass the analysis of ploidy, cell cycle kinetics, and the presence of specific 
antigens (Dolezel et al., 2004). Flow cytometers and sorters have become a 
widespread and vital resource in the biological sciences and beyond. It is a process 
that allows the physical separation of a cell or particle of interest from a 
heterogeneous population.  
 
1.2.2 Flow cytogenetics 
Early discussions about sequencing the entire human genome were considered 
credible in large part due to the ability to flow sort, with high purity, each of the 
human chromosomes. High-purity sorting made it possible to clone and produce 
chromosome-specific libraries suitable for sequencing (Cram et al., 2004).   
At first, it seems improbable that the founders of flow cytometry thought of 
analyzing chromosomes with these instruments. Yet, the meeting of flow cytometry 
and cytogenetics gave rise to a whole new area of research called flow cytogenetics. 
Flow cytogenetics describes the application of flow cytometry for analysis and 
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sorting of mitotic chromosome classification and purification (Cram et al., 2002). 
Flow cytogenetics has contributed significantly to the progress in many areas of 
genome analysis and mapping as well as underpinning the sequencing of the human 
genome (Dolezel et al., 2004).  
The underlying principles of flow cytogenetics are relatively straightforward. 
The chromosomes in an aqueous suspension are constrained to flow in a single file 
within a fluid stream and past a narrow beam of excitation light. During the short 
time each chromosome is in the light beam, the light is scattered and the molecules 
of fluorochrome bound to the chromosomes are excited.  
In flow cytogenetics, a large number of fluorescent dyes are capable of 
interacting with DNA. When such dyes are used individually to stain cells or 
chromosomes, their fluorescence can be influenced not only by the amount of DNA 
present but by the DNA base composition (Latt et al., 1979). The persistent problem 
was the inability to resolve all chromosomes within a karyotype due to the similarity 
of relative DNA content (Dolezel et al., 2004). This was overcome by improving the 
existing procedures for chromosome isolation and by staining the chromosome 
preparation with two dyes differing in base pair preference, such as Hoechst 33258 
and Chromomycin A3 (Latt et al., 1979). Although various other approaches were 
introduced to improve chromosome discrimination, bivariate analysis using Hoechst 
and Chromomycin has become the gold standard for chromosome analysis using 
flow cytometry/flow karyotyping in human and animals (Dolezel et al., 2004). 
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1.2.3 Flow karyotype 
Flow karyotyping provides precise information about chromosome properties, 
such as DNA content for several hundred thousand chromosomes (Cram et al., 2002). 
A flow karyotype is the distribution of relative fluorescence intensity of individual 
chromosomes or groups of chromosomes of similar relative DNA content. This 
opened an exciting avenue towards the purification of individual chromosomes by 
flow sorting (Dolezel et al., 2004). Flow karyotyping requires isolation of intact 
metaphase chromosomes, staining the chromosome suspension with a fluorescent tag, 
and rapid quantitative analysis in a flow cytometer.  
Applications of univariate (one colour) flow karyotype analysis include 
determining and monitoring karyotype instability, variation in the frequency of a 
chromosome type, chromosomal polymorphisms, and chromosome rearrangements. 
For univariate flow karyotyping, chromosome discrimination is based on the amount 
of fluorescent dye bound to the chromosome. Many of the fluorochromes used for 
flow karyotyping bind only to nucleic acids so that discrimination is largely based on 
total DNA content.  
Bivariate flow karyotyping, where chromosome classification is based on two 
fluorochromes, was developed to take advantage of the fact that some dyes like 
Hoechst 33258 and Chromomycin CA3 bind preferentially to adenine-thymine (AT) 
or guanine-cytosine (GC) rich DNA, respectively. This pair of fluorochromes allows 
classification of chromosomes according to DNA content and DNA base 
composition. Figure 1.6 shows a typical bivariate human flow karyogram and Table 
1.3 shows the size of all the human chromosomes and the estimation of known 
protein-coding genes in each chromosome. 
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Figure 1.6 A typical bivariate flow karyogram of a normal human male cell (Cram et 
al., 2002). Adapted from Figure 5, page 30, Cram et al., 2002. 
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Table 1.3 Human chromosome sizes and an estimate of the number of known 
protein-coding genes of each chromosome 
 
Chromosome Size (bp) Number of known protein-coding genes 
1 249,250,621 2029 
2 243,199,373 1230 
3 198,022,430 1055 
4 191,154,276 796 
5 180,915,260 867 
6 171,115,067 1022 
7 159,138,663 973 
8 146,364,022 755 
9 141,213,431 806 
10 135,534,747 767 
11 135,006,516 1352 
12 133,851,895 1051 
13 115,169,878 324 
14 107,349,540 633 
15 102,531,392 671 
16 90,354,753 907 
17 81,195,210 1184 
18 78,077,248 287 
19 59,128,983 1456 
20 63,025,520 551 
21 48,129,895 235 
22 51,304,566 445 
X 155,270,560 833 
Y 59,373,566 48 
Notes: Chromosome sizes and number of known protein-coding genes according to 
GRCh37 from Ensembl (Ensembl, 2010). 
 
1.2.4 Chromosome sorting 
Chromosome isolation consists of freeing individual chromosomes from 
mitotic cells and stabilizing their structure. Staining reactions are designed to label a 
mixture of chromosome types so that one chromosome type is distinguished from 
another. The ultimate goal is to resolve each chromosome type from any given 
species. Chromosome purification by sorting requires the highest possible 
discrimination of chromosome types from one another and from chromosomal debris 
and clumps. In the case of chromosomes isolated from human cells, this means 
